Phaseline

Targets › SCNN1A

SCNN1A (Epithelial sodium channel subunit alpha): drug programs, companies and trials

4 programs from 4 companies in 11 trials: 7 Phase 2, 2 Phase 4, 1 Phase 1, 1 Phase 3; Cardiovascular, Neurology, Gastroenterology; next expected readout Dec 2026.

This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis. ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically. (UniProt, P37088)

Open in Phaseline: the race on SCNN1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Odense University HospitalCapsule FMT
Amiloride-sensitive sodium channel, ENaC blocker
GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1GPhase 4Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women …Dec 2026
Assistance Publique - Hôpitaux de ParisAmiloride
Amiloride-sensitive sodium channel, ENaC blocker
SCNN1A, SCNN1B, SCNN1GPhase 4Bipolar Disorder–
Centre Hospitalier Universitaire de NiceAmiloride
Amiloride-sensitive sodium channel, ENaC blocker
SCNN1A, SCNN1B, SCNN1GPhase 2Migraine With AuraDec 2027
Yale UniversityAmiloride
Amiloride-sensitive sodium channel, ENaC blocker
SCNN1A, SCNN1B, SCNN1GPhase 1Heart FailureJun 2028

Conditions

Heart Failure (1) Migraine With Aura (1) Gastroesophageal Reflux (1) Colitis (1) Chronic Kidney Disease(CKD) (1) Postmenopausal Women (1) Type 2 Diabetes (1) Rheumatoid Arthritis (1) Healthy (1) Cancer of Rectum (1) Bipolar Disorder (1)

Modalities

small molecule (3), protein or peptide (1)

Companies

Yale University (1) Centre Hospitalier Universitaire de Nice (1) Odense University Hospital (1) Assistance Publique - Hôpitaux de Paris (1)

Related targets

SCNN1B (4) SCNN1G (4) GLP1R (1) ATP4A (1) ATP4B (1) CTLA4 (1) FKBP1A (1) TNF (1) PDCD1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.